Grant received in 2023
DCCC has funded 200.000 DKK to the project.
Almost 1,000 Danes die of pancreatic cancer (PC) every year because there is no curative treatment. There is a great need for new treatments and biomarkers. Intensive research is being focused on more tailored treatment with the patient's DNA structure in focus. And in recent years – the known genetic methods are getting better and new substances that enter the cells and target what causes the tumor to grow are introduced.
This supports the idea that the more individualized treatment can improve survival. Patients with gene mutations that can cause cancer and for which there are targeted drugs will be randomized between targeted cancer drug or the standard treatment.
The aim of this DPCG-initiated study is to evaluate, if molecularly tailored therapy is superior to standard of care, as second line treatment in terms of progression-free survival, in patients with PC harboring actionable molecular alterations.
Multidisciplinary organisation
Dansk Pancreas Cancer Gruppe (DPCG)
Project stakeholders
- Inna Chen, Senior Physician, Head, Knowledge Center for Medical Treatment of Pancreatic Cancer, Herlev and Gentofte Hospital. Primary contact person, e-mail: inna.Chen@regionh.dk
- Per Pfeiffer, Senior Physician, Professor, Oncology Department, Odense University Hospital
- Morten Ladekarl, Senior Physician, Professor, Oncology Department, Aalborg University Hospital
- Torben Frøstrup Hansen, Senior Physician, Professor, Oncology Department, Vejle Hospital
- Britta Weber, Senior Physician, Oncology Department, Aarhus University Hospital
- Gabor Istvan Liposits, Senior Physician, Herning Hospital
- Maria Rossing, Consultant, associate professor, Department of Genomic Medicine, Rigshospitalet
- Julia Sidenius Johansen, Senior Physician, Professor Oncology Department, Herlev & Gentofte University Hospital
- Søren Brunak, Professor, Novo Nordisk Foundation Center for Protein Research
- The established collaborative relationships represent almost all oncological pancreatic cancer patients in Denmark.
- Other Danish oncology centers are asked about participation after preparation of the protocol synopsis